
FIG. 1


Screening
Baseline
Double-Masked Treatment Period Teprotumumab or Placebo [1] 24 Weeks [2]
Follow-up Period 24 Weeks [3]
Clinic Visits
Clinic or Phone/email Visits
4 Weeks Predose
Day 1[4]
W3[4]
W6
W9
W12 M3
W15
W18
W21
W24[5] M6
W28 M7
W32[6] M8
W36 M9
W42[6]
W48[7] M12
Randomization[1]
Study Week/Month